Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.

Fisher, Bernard; Dignam, James J.; Mamounas, Eleftherios P.; Costantino, Joseph P.; Wickerham, D. Lawrence; Redmond, Carol; Wolmark, Norman; Dimitrov, Nikolay V.; Bowman, D. M. J. S.; Glass, Andrew G.; Atkins, James N.; Abramson, Neil; Sutherland, Carl M.; Aron, Bernard S.; Margolese, Richard G.

doi:10.1200/jco.1996.14.7.1982

Cited by 215 publications

(98 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among the 235 patients treated with conservative surgery and radiation therapy, the eight-year rate of recurrence in the ipsilateral breast was 13.4 percent without chemotherapy and only 2.6 percent with chemotherapy. 50 Similar results are seen with adjuvant tamoxifen. In NSABP trial B-14, node-negative ER-positive patients were randomized to tamoxifen or to a placebo.…”

Section: Elements Of the Breast Physical Examsupporting

confidence: 75%

Standard for Breast Conservation Therapy in the Management of Invasive Breast Carcinoma

Morrow

Strom

Bassett

et al. 2002

CA: A Cancer Journal for Clinicians

298

165

View full text Add to dashboard Cite

Multidisciplinary guidelines for management of invasive breast carcinoma from the American College of Radiology, the American College of Surgeons, the College of American Pathology, and the Society of Surgical Oncology have been updated to reflect the continuing advances in the diagnosis and treatment of invasive breast cancer. The guidelines provide a framework for clinical decision‐making for patients with invasive breast carcinoma based on review of relevant literature and include information on patient selection and evaluation, technical aspects of surgical treatment, techniques of irradiation, and follow‐up care.

show abstract

Section: Elements Of the Breast Physical Examsupporting

confidence: 75%

Standard for Breast Conservation Therapy in the Management of Invasive Breast Carcinoma

Morrow

Strom

Bassett

et al. 2002

CA: A Cancer Journal for Clinicians

298

165

View full text Add to dashboard Cite

show abstract

“…Over 8 years of follow-up. 42 Just as first reported after 5 years, 44 the results continue to demonstrate a statistically significant DFS and OS advantage with CMF over MF (P= 0.003 an P=0.03 respectively, figure 7). Those advantages were most evident in women aged <50 years (P=0.0004 and P=0.007 respectively).…”

Section: Studies In Patients With Er-negative Tumorssupporting

confidence: 62%

“…Findings over the course of 14 years of follow-up 42 demonstrate that the improvements from MF in DFS and OS, previously reported after five 43 and eight 44 years, have persisted (P<0.0001 in the former and P=0.02 in the latter, figure 6). A statistically significant benefit in DFS was evident both for women <50 years of age (P=0.005) as well as those ≥50 years (P=0.001).…”

Section: Studies In Patients With Er-negative Tumorsmentioning

confidence: 66%

NSABP Breast Cancer Clinical Trials: Recent Results and Future Directions

Mamounas¹

2003

Clinical Medicine & Research

View full text Add to dashboard Cite

Over the past 40 years, the National Surgical Adjuvant Breast and Bowel Project (NSABP) has conducted several large, randomized clinical trials evaluating various aspects of surgical and adjuvant therapy in patients with operable breast cancer. Results from these trials have contributed significantly in reducing the extent of surgical procedures and in improving the outcome of patients with early-stage breast cancer. Furthermore, they have helped to establish standards of care for the surgical management of invasive and non-invasive disease and for the use of adjuvant hormonal therapy and adjuvant chemotherapy for patients with negative as well as for those with positive axillary nodes. More recent trials are evaluating several new classes of promising drugs such as the aromatase inhibitors in postmenopausal women with invasive or intraductal breast cancer, the taxanes for patients with positive nodes and in the neoadjuvant setting and other targeted molecular therapies such as trastuzumab and bisphosphonates. Results from these ongoing and recently completed trials could improve outcomes and quality of life for patients with early-stage breast cancer.

show abstract

“…Adjuvant systemic therapy significantly reduces locoregional recurrence, [27][28][29] and neoadjuvant medical therapy can eradicate axillary lymph node metastases. 30 The subtypes may be predictive of locoregional recurrence and survival even after postmastectomy radiotherapy and neoadjuvant chemotherapy.…”

Section: Author's Personal Copymentioning

confidence: 99%

Does Conservative Surgery for Breast Carcinoma Still Require Axillary Lymph Node Evaluation? A Retrospective Analysis of 1156 Consecutive Women With Early Breast Cancer

Marrazzo

Damiano

Taörmina³

et al. 2017

Clinical Breast Cancer

View full text Add to dashboard Cite

We performed a retrospective analysis of 1156 patients affected by early breast cancer in order to estimate the real incidence of patients with T1 tumors presenting > 2 metastatic lymph nodes. The advantage of axillary surgery seems to be limited only to a specific subgroup of T1 patients who are undergoing conservative surgery plus radiotherapy. Background: The role of axillary surgery for early breast carcinoma treated with conservative surgery and radiotherapy is currently the subject of considerable investigation. Recent studies have supported the noninferiority of avoiding axillary surgery in terms of overall survival when sentinel lymph node biopsy (SLNB) presents 2 positive lymph nodes, thus sparing the patients from complications. There are some ongoing studies investigating the possibility of omitting SLNB. Axillary study seems to be sufficiently replaced by SLNB for staging the disease. Axillary surgery maintains a therapeutic role in the presence of > 2 metastatic lymph nodes at SLNB. Patients and Methods: We performed a retrospective analysis of 1156 patients with early breast cancer to estimate the real incidence of patients with T1 tumors presenting > 2 metastatic lymph nodes. Results: Of the 1156 cases, only 106 (9.2%) had > 2 axillary metastatic lymph nodes. More specifically, 38 (4.3%) of 884 T1 cases, and 6 (2.3%) of 257 of T1b cases had > 2 metastatic lymph nodes. Conclusion: The advantage of axillary surgery seems to be limited only to a specific subgroup of T1 patients who are undergoing conservative surgery plus radiotherapy. The ongoing studies on avoiding SLNB will likely prove the noninferiority of omitting biopsy because these studies are conducted in the whole population of early breast cancers. It is necessary to identify more accurately the subpopulation of patients who may benefit from axillary surgery.

show abstract

Cited by 215 publications

References 9 publications

Standard for Breast Conservation Therapy in the Management of Invasive Breast Carcinoma

Standard for Breast Conservation Therapy in the Management of Invasive Breast Carcinoma

NSABP Breast Cancer Clinical Trials: Recent Results and Future Directions

Does Conservative Surgery for Breast Carcinoma Still Require Axillary Lymph Node Evaluation? A Retrospective Analysis of 1156 Consecutive Women With Early Breast Cancer

Contact Info

Product

Resources

About